MedPath

Modified SALT Score for Alopecia Areata

Phase 4
Conditions
Alopecia Areata
Interventions
Registration Number
NCT04412148
Lead Sponsor
Kasr El Aini Hospital
Brief Summary

Patchy Alopecia areata was treated by intralesional steroids for 3 months and was evaluated by percentage of involvement, mSALT score and dermoscopy.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • localized scalp AA ( 2 patches and ≤50% scalp involvement , duration more than 6 months) • patients who did not receive any medication for at least 2 months before starting the study and those who agreed to join the study and signed written consent.
Exclusion Criteria
  • • pregnant, and lactating females

    • Alopecia totalis or universalis or ophiasis or cicatritial alopecia
    • Usage of systemic treatment of alopecia areata 2 months prior to the study.
    • Any scalp lesion within the treated area
    • Bleeding diathesis, severe anemia or platelet disorders
    • Medical conditions such as autoimmune diseases.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Intralesional SteroidsTriamcinolone Acetonide-
Controlsaline-
Primary Outcome Measures
NameTimeMethod
Percentage involvement6months to 1 year

Degree of severity expressed as a percentage

Modified Severity of Alopecia Tool (mSALT) score6 months to 1 year

New Score calculating severity (hair density) and area as a number minimum value is 0 and maximum value is 105 the higher the number of the score the worse the affection

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kasr El Ainy university hospital, Faulty of medicine,Cairo university

🇪🇬

Cairo, Egypt

Kasr El Ainy university hospital, Faulty of medicine,Cairo university
🇪🇬Cairo, Egypt
Rana Hilal, MD
Contact
1001488869
rana.hilal@kasralainy.edu.eg

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.